SG Americas Securities
CCCC icon

SG Americas Securities’s C4 Therapeutics CCCC Stock Holding History

SG Americas Securities’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-425,096
Closed -$680K – 3002
2025
Q1 		$680K Buy
+425,096
New +$1.27M ﹤0.01% 1515
2024
Q4 		– Sell
-24,941
Closed -$142K – 3184
2024
Q3 		$142K Buy
+24,941
New +$150K ﹤0.01% 2780
2024
Q2 		– Sell
-22,368
Closed -$183K – 2899
2024
Q1 		$183K Buy
+22,368
New +$173K ﹤0.01% 2039
2023
Q4 		– Sell
-11,921
Closed -$22K – 3138
2023
Q3 		$22K Sell
11,921
-889
-7% -$2.71K ﹤0.01% 3038
2023
Q2 		$35K Sell
12,810
-15,203
-54% -$48.9K ﹤0.01% 2155
2023
Q1 		$88K Sell
28,013
-13,532
-33% -$79.7K ﹤0.01% 2952
2022
Q4 		$245K Buy
41,545
+2,087
+5% +$17.3K ﹤0.01% 2063
2022
Q3 		$346K Buy
39,458
+7,785
+25% +$80.8K ﹤0.01% 1871
2022
Q2 		$239K Buy
+31,673
New +$279K ﹤0.01% 2540
2022
Q1 		– Sell
-7,149
Closed -$230K – 3012
2021
Q4 		$230K Sell
7,149
-4,592
-39% -$182K ﹤0.01% 2599
2021
Q3 		$525K Buy
11,741
+7,451
+174% +$319K ﹤0.01% 2459
2021
Q2 		$162K Buy
4,290
+318
+8% +$11.4K ﹤0.01% 2430
2021
Q1 		$147K Buy
+3,972
New +$158K ﹤0.01% 2866

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG Americas Securities's CCCC Position: Q2 2025 in Review

SG Americas Securities sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 425,096 shares — an estimated $680K sold.

SG Americas Securities first reported a position in CCCC in Q1 2021 and held it in 13 quarters. The position peaked at $680K in Q1 2025. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • SG Americas Securities reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 425,096 C4 Therapeutics shares in Q2 2025, an estimated $680K.
  • SG Americas Securities first reported a position in C4 Therapeutics in Q1 2021 and held it in 13 quarters.
  • SG Americas Securities's C4 Therapeutics position peaked at $680K in Q1 2025.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.